Age disparities in clinical trials of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with high grade serous ovarian cancer: A wake up call to improving outcomes in older patients.

IF 3 3区医学 Q3 GERIATRICS & GERONTOLOGY

Journal of geriatric oncology Pub Date : 2024-11-12 DOI:10.1016/j.jgo.2024.102152

Omali Pitiyarachchi, Michael Friedlander

引用次数: 0

查看原文本刊更多论文

针对高级别浆液性卵巢癌患者的多（ADP-核糖）聚合酶（PARP）抑制剂临床试验中的年龄差异：提高老年患者治疗效果的警钟。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of geriatric oncology ONCOLOGY-GERIATRICS & GERONTOLOGY

CiteScore

5.30

自引率

10.00%

发文量

379

审稿时长

80 days

期刊介绍： The Journal of Geriatric Oncology is an international, multidisciplinary journal which is focused on advancing research in the treatment and survivorship issues of older adults with cancer, as well as literature relevant to education and policy development in geriatric oncology. The journal welcomes the submission of manuscripts in the following categories: • Original research articles • Review articles • Clinical trials • Education and training articles • Short communications • Perspectives • Meeting reports • Letters to the Editor.